Abstract:The extracellular signal-regulated kinase 2 (ERK2) protein plays a pivotal role in regulating cell division cycles and signaling pathways essential for various biological processes. ERK2 inhibition is a promising therapeutic approach for diseases like cardiovascular deformities, neurodegenerative disorders, and other forms of cancers. The current study presents novel compounds potentially inhibiting ERK2 activity, thus disrupting its cellular functions. A thorough structural assessment of the available crystallographic information was undertaken. The protein's active site was deciphered, and the experimental grid space of inhibitors interaction was allocated. The study proceeded further with a precise inhibitor search employing a "similarity search" algorithm based on the previously reported kinase inhibitors. Schematic virtual screening method combined with molecular docking steps were executed to enlist the probable hits. AI/ML-based pharmacokinetics properties helped streamline hits' initial chemical space and select the most potent leads. Complexes formed by these compounds were analyzed for their stability by molecular dynamics (MD) simulations. Post dynamics statistical calculations, viz., protein backbone and ligand RMSD, the radius of gyration, and the constitutive amino acids fluctuations (RMSF), confirmed the protein–ligand association over a period of 300 ns. The magnitude of co-ordinations was estimated by intermolecular H-bond count and the MMGBSA calculations. The free energy landscape (FEL) and principal component analysis (PCA) demonstrated the thermodynamical feasibility of the complex formation with an affinity greater than the previously reported inhibitors. This study, thus, presents a promising avenue for advancing the drug discovery process by identifying novel ERK2 protein inhibitors with potential benefits for healthcare.

Identification and Benchmarking of Myokinasib-II as a Selective and Potent Chemical Probe for Exploring MLCK1 Inhibition

Identification and benchmarking of Myokinasib-II as a highly selective and potent chemical probe for exploring MLCK1 inhibition

Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic Potential

Pharmacophore development, drug-likeness analysis, molecular docking, and molecular dynamics simulations for identification of new CK2 inhibitors

Machine learning-integrated and fingerprint-based similarity search against immuno oncology library for identification of novel ERK2 inhibitors

Design, synthesis and biological evaluation of MNK-PROTACs

A Road Map to Evaluate the Proteome-Wide Selectivity of Covalent Kinase Inhibitors.

Identifying dual leucine zipper kinase (DLK) inhibitors using e-pharamacophore screening and molecular docking

Identification of CK2α’ selective inhibitors by the screening of an allosteric-kinase-inhibitor-like compound library

Synthesis and evaluation of chemical linchpins for highly selective CK2α targeting

Identification of Novel Inhibitors Targeting SGK1 via Ensemble-Based Virtual Screening Method, Biological Evaluation and Molecular Dynamics Simulation

Development of a Covalent Inhibitor of C-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1.

Identification of inhibitors for neurodegenerative diseases targeting dual leucine zipper kinase through virtual screening and molecular dynamics simulations

Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking

Identifying The Proteins To Which Small-Molecule Probes And Drugs Bind In Cells

Identification and Optimisation of Novel and Selective Small Molecular Weight Kinase Inhibitors of Mtor

Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2

CellEKT: A robust chemical proteomics workflow to profile cellular target engagement of kinase inhibitors

Identification, Structure Modification, and Characterization of Potential Small-Molecule SGK3 Inhibitors with Novel Scaffolds

Identification of Novel GSK-3β Hits Using Competitive Biophysical Assays

Discovery of a new class of highly potent necroptosis inhibitors targeting the mixed lineage kinase domain-like protein.